CA-WETA-DIGITAL
17.12.2020 18:17:18 CET | Business Wire | Press release
Weta Digital, one of the world’s premiere visual effects facilities and parent company of Weta Animated, has announced the addition of industry leaders Tom Staggs, Jeff Huber and Ken Kamins to its Board of Directors. The appointment of Staggs, Huber and Kamins reflect the continued growth and innovation of the company, which is also opening offices in Los Angeles and San Francisco.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201217005350/en/
“Tom, Jeff and Ken are extraordinary additions to the board of Weta Digital,” said Prem Akkaraju, Global CEO of Weta Digital. “They have established best practices at the highest levels of company management, in entertainment and digital technology. Their combined business acumen and collective depth of experience perfectly positions Weta Digital for exponential growth. Opening offices in Los Angeles and San Francisco enables storytellers to tap Weta’s production pipeline and work with concept designers, animation supervisors and other key creatives, in both the US and New Zealand. Weta Digital’s expansion comes at a time when much of the film industry is experiencing extraordinary uncertainty as we grapple with the ongoing impact of Covid-19. We’re extremely fortunate that New Zealand got in front of the curve early - it’s one of the few places in the world that has managed community transmission, where you can make a film safely, without the restrictive protocols of other markets.”
Tom Staggs brings more than 26-years of experience at The Walt Disney Company, including 18 years of C-suite experience with the company. He was most recently Disney’s Chief Operating Officer, having previously served for five years as Chairman of Disney Parks and Resorts Worldwide and for nearly 12 years as Disney’s Chief Financial Officer. During his time at Disney, Staggs helped shape Disney’s strategic, financial, operational, creative and brand management strategies across every segment of the company and helped drive many of Disney’s most important initiatives including the acquisitions of Cap Cities/ABC, Pixar and Marvel. Since departing Disney in late 2016, Staggs has focused on developing several new business ventures across a variety of fields. He is a board member and advisor to a number of private companies, and also serves on the board of directors of music streaming service Spotify. Before joining Disney, Staggs was an investment banker at Morgan Stanley and Dain Bosworth.
“I have long admired Peter Jackson and Fran Walsh’s filmmaking talents and Weta Digital’s accomplishments in animation and visual effects. Weta Digital’s rare combination of creative talent and technology gives them a unique ability to succeed in high-end animation production,” said Staggs. “I look forward to working with Peter, Fran, Prem and the entire Weta Digital team on the animation business and further global expansion.”
Jeff Huber is the former Founding CEO and Vice Chairman of GRAIL and previously a Senior Vice President at Google. Having spent over 13 years at Google, Huber co-founded the company’s life sciences efforts in Google X and led development and scaling for Google Maps, Google Apps and Google Ads. During his tenure as an executive at Google, Jeff oversaw 50x growth in revenues (from $1 billion to >$50 billion) and organization (1,000 to >50,000 employees), and managed a $5 billion P&L and large distributed teams (5,000+ direct-line employees). Prior to Google, Huber served as Vice President of Architecture and Systems Development at eBay and Senior Vice President of Engineering at Excite@Home, where he led consumer product and infrastructure development.
"Weta Digital is known around the world for its astounding visual effects and inventive storytelling. This amazing artistry is driven by groundbreaking technology and non-stop innovation,” said Huber. “The research and development teams at Weta Digital have consistently produced magic and raised the bar as to what is possible. I look forward to the adventures ahead with Peter, Fran, Prem and the entire Weta Digital Team, growing the company in scale and technology excellence to create the next generation of culture-defining stories and experiences."
Ken Kamins is the Founder and CEO of Key Creatives, a management-production company. He has represented Peter Jackson and Fran Walsh since 1992, and his Executive Producer credits include The Hobbit Trilogy , District 9 , and The Adventures of Tintin: The Secret of the Unicorn. Prior to his current position, he served as Executive Vice President of the talent agency, International Creative Management; and before that, as Executive Vice President of RCA/Columbia Pictures Home Entertainment.
“I’ve had a front row seat for the entire growth curve of Weta Digital, from its beginnings in 1993 when the company consisted of just one computer and one artist creating the digital effects in “Heavenly Creatures”, through to this moment,” said Kamins. “Weta Digital was designed by Peter and Fran to be a creative haven for filmmakers - a place where they could let their imaginations run wild. No idea was too crazy or too difficult to try. In collaboration with the many great artists Weta has had the privilege to work with, Joe Letteri, David Conley and their teams have consistently pushed the boundaries of imaginative storytelling.”
Staggs, Huber and Kamins join Weta Digital board members Peter Jackson, Fran Walsh, Sean Parker, Joe Letteri and CEO Prem Akkaraju.
ABOUT WETA DIGITAL:
Weta Digital is the standard-bearer for creativity and innovation in visual effects and animation, attracting talent, partners, and clients that seek to push what is possible in pursuit of their artistic vision. Weta’s proprietary pipeline continues to evolve and provide artists with the tools they need to create their best work. Based in Wellington, New Zealand, Weta Digital is the largest single-site VFX studio in the world drawing artists from over 40 countries. They are some of the most creative and ambitious artists, engineers, and executives in entertainment and their work has earned six visual effects Academy Awards, ten Academy Sci-Tech Awards and six visual effects BAFTA Awards in addition to the 34 Visual Effects Society Awards awarded to them by their peers. Ground-breaking, performance-driven animated characters from Gollum to Caesar, and worlds from Middle-earth to Pandora, are regarded as some of the best visual effects ever to appear on screen.
For more information:
Corporate: www.wetastudios.com
Weta Digital: www.wetafx.co.nz
Follow: @weta_digital
View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005350/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
